# US 2025/0154167 A1 · Method of treatment of symptoms of menopause

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154167 A1
- Document ID: US20250154167A1
- Status: Published application
- Kind: A1
- Application number: 19/025,725
- Filed: 2025-01-16
- Published: 2025-05-15
- Earliest claimed: 2018-03-14
- Assignees: KaNDy Therapeutics Limited
- Applicants: KaNDy Therapeutics Limited
- Inventors: Mike TROWER; Monica LAZARO; Derek BUSH; David ELDER; Mary KERR
- Web page: https://patentgrep.com/patent/US20250154167A1

## CPC

- C07D 498/04: Ortho-condensed systems
- A61K 9/4858: {Organic compounds}
- A61K 31/5383: ortho- or peri-condensed with heterocyclic ring systems
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 25/00: Drugs for disorders of the nervous system
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4] oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.

## Claims

### Claim 1

A method of treating a symptom of the perimenopause, the menopause, the post menopause or a symptom associated with the andropause comprising administering to a human in need thereof an effective amount of Compound of formula (A) or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the symptom of the perimenopause, the menopause, or the post menopause is selected from insomnia, sleep disturbances and night-time awakenings, depression and anxiety, decreases in sexual desire and vaginal dryness, symptoms caused by chemotherapy, urinary symptoms of urgency and dysuria, pathological gain of excess body fat and/or excess body weight.

### Claim 3 (depends on 1)

The method of claim 1, wherein the symptom of the andropause is selected from insomnia, sleep disturbances and night-time awakenings, depression and anxiety, decreases in sexual desire, symptoms caused by chemotherapy, urinary symptoms of urgency and dysuria, pathological gain of excess body fat and/or excess body weight.

### Claim 4 (depends on 1)

The method of claim 1, wherein the Compound of formula (A) is in a crystalline anhydrate form.

### Claim 5 (depends on 1)

The method of claim 1, wherein the Compound of formula (A) is in crystalline anhydrate Form 1, characterized by X-ray powder diffraction (XRD) pattern expressed in terms of 2 theta angles, wherein the XRD pattern comprises 2 theta angle peaks at 4.3±0.1, 7.9±0.1, 9.8±0.1, 10.7±0.1, 10.8±0.1, 13.3±0.1, 14.0±0.1, 15.1±0.1 degrees, which correspond respectively to d-spacing at 20.4, 11.1, 9.0, 8.3, 8.2, 6.6, 6.3 and 5.9 Angstroms (Å).

### Claim 6 (depends on 1)

The method of claim 1 further comprising administering to the subject in need thereof one or more additional therapeutic agents.

### Claim 7 (depends on 1)

The method of claim 1, wherein the Compound (A) is administered as a soft gelatin capsule comprising:
(a) Compound A or a pharmaceutically acceptable salt thereof;
(b) at least one solubilizer selected from caprylocaproyl polyoxyl-8 glycerides, glycerol monocaprylocaprate, polyoxyl 35 castor oil, polysorbate 80, or mixtures thereof; and
(c) at least one antioxidant selected from d1-alpha-tocopherol, butylated hydroxytoluene, butylated hydroxyanisole or mixtures thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the Compound (A) is administered as a soft gelatin capsule comprising
(a) Compound A or a pharmaceutically acceptable salt thereof;
(b) at least one solubilizer selected from caprylocaproyl polyoxyl-8 glycerides, glycerol monocaprylocaprate, polyoxyl 35 castor oil, polysorbate 80, or mixtures thereof;
(c) at least one antioxidant selected from dl-alpha-tocopherol, butylated hydroxytoluene, butylated hydroxyanisole or mixtures thereof; and
(d) at least one emulsifier selected from glyceryl monooleate, Miglyol 812, or a mixture thereof.

### Claim 9 (depends on 7)

The method of claim 7, wherein Compound A is present in the soft gelatin capsule in an amount from 10 mg to 80 mg.

### Claim 10 (depends on 7, 8)

The method of claim 8, wherein Compound A is present in the soft gelatin capsule in an amount from 10 mg to 80 mg. 11 The method of claim 7, wherein Compound A is present in the soft gelatin capsule at a concentration ranging from 0.8% w/w to 15% w/w or from 5% w/w to 10% w/w.

### Claim 12 (depends on 8)

The method of claim 8, wherein Compound A is present in the soft gelatin capsule at a concentration ranging from 0.8% w/w to 15% w/w or from 5% w/w to 10% w/w.

### Claim 13 (depends on 7)

The method of claim 7, wherein at least one solubilizer is selected from glycerol monocaprylocaprate, caprylocaproyl polyoxyl-8 glycerides, or polysorbate 80.

### Claim 14 (depends on 8)

The method of claim 8, wherein at least one solubilizer is selected from glycerol monocaprylocaprate, caprylocaproyl polyoxyl-8 glycerides, or polysorbate 80.

### Claim 15 (depends on 8)

The method of claim 8, wherein the at least one emulsifier is glyceryl monooleate.

### Claim 16 (depends on 7)

The method of claim 7, wherein at least one antioxidant is dl-alpha-tocopherol.

### Claim 17 (depends on 8)

The method of claim 8, wherein at least one antioxidant is dl-alpha-tocopherol.

### Claim 18 (depends on 1)

The method of claim 1, wherein the Compound (A) is administered as a soft gelatin capsule comprising:
(a) Compound A;
(b1) glycerol monocaprylocaprate;
(b2) caprylocaproyl polyoxyl-8-glycerides;
(b3) polysorbate 80; and
(c) dl-alpha-tocopherol.

### Claim 19 (depends on 1)

The method of claim 1, wherein the Compound (A) is administered as a soft gelatin capsule comprising:
(a) Compound A;
(b1) glycerol monocaprylocaprate;
(b2) caprylocaproyl polyoxyl-8-glycerides;
(b3) polysorbate 80;
(c) dl-alpha-tocopherol; and
(d) glyceryl monooleate.

### Claim 20 (depends on 13)

The method of claim 13, wherein glycerol monocaprylocaprate is present in the soft gelatin capsule at a concentration ranging from 20% w/w to 65% w/w.

### Claim 21 (depends on 14)

The method of claim 14, wherein glycerol monocaprylocaprate is present in the soft gelatin capsule at a concentration ranging from 20% w/w to 65% w/w.

### Claim 22 (depends on 13)

The method of claim 13, wherein caprylocaproyl polyoxyl-8 glycerides is present in the soft gelatin capsule at a concentration ranging from 7% w/w to 13% w/w.

### Claim 23 (depends on 14)

The method of claim 14, wherein caprylocaproyl polyoxyl-8 glycerides is present in the soft gelatin capsule at a concentration ranging from 7% w/w to 13% w/w.

### Claim 24 (depends on 13)

The method of claim 13, wherein polysorbate 80 is present in the soft gelatin capsule at a concentration from 7% w/w to 13% w/w.

### Claim 25 (depends on 14)

The method of claim 14, wherein polysorbate 80 is present in the soft gelatin capsule at a concentration from 7% w/w to 13% w/w.

### Claim 26 (depends on 15)

The method of claim 15, wherein glyceryl monooleate is present in the soft gelatin capsule at a concentration ranging from 15% w/w to 60% w/w.

### Claim 27 (depends on 16)

The method of claim 16, wherein dl-alpha-tocopherol is present in the soft gelatin capsule at a concentration ranging from 0.05% w/w to 1.5% w/w.

### Claim 28 (depends on 17)

The method of claim 17, wherein dl-alpha-tocopherol is present in the soft gelatin capsule at a concentration ranging from 0.05% w/w to 1.5% w/w.

### Claim 29 (depends on 1)

The method of claim 1, wherein the Compound (A) is administered as a soft gelatin capsule comprising:
(a) Compound A present at a concentration ranging from 5% w/w to 10% w/w;
(b1) glycerol monocaprylocaprate present at a concentration ranging from 20% w/w to 65% w/w;
(b2) caprylocaproyl polyoxyl-8 glycerides present at a concentration ranging from 7% w/w to 13% w/w;
(b3) polysorbate 80 present at a concentration from 7% w/w to 13% w/w;
(c) dl-alpha-tocopherol present at a concentration ranging from 0.5% w/w to 1% w/w and
(d) glyceryl monooleate.

### Claim 30 (depends on 29)

The method of claim 29, wherein the Compound A is administered as a soft gelatin capsule being prepared by a method comprising adding Compound A to a mixture comprising 15% w/w to 60% w/w glyceryl monooleate, glycerol monocaprylocaprate, caprylocaproyl polyoxyl-8 glycerides, polysorbate 80, or dl-alpha-tocopherol.

### Claim 31 (depends on 1)

The method of claim 1, wherein the Compound A is administered as a soft gelatin capsule comprising:
a) Compound A present at a concentration ranging from 5% w/w to 10% w/w;
(b1) glycerol monocaprylocaprate present at a concentration ranging from 20% w/w to 65% w/w;
(b2) caprylocaproyl polyoxyl-8 glycerides present at a concentration ranging from 7% w/w to 13% w/w;
(b3) polysorbate 80 present at a concentration from 7% w/w to 13% w/w;
(c) dl-alpha-tocopherol present at a concentration ranging from 0.5% w/w to 1% w/w; and
(d) glyceryl monooleate present at a concentration ranging from 15% w/w to 60% w/w.

### Claim 32 (depends on 1)

The method of claim 1, wherein the Compound (A) is administered as a soft gelatin capsule comprising:
(a) Compound A present at a concentration ranging from 1% w/w to 10% w/w;
(b1) glycerol monocaprylocaprate present at a concentration ranging 30% w/w to 40% w/w;
(b2) caprylocaproyl polyoxyl-8 glycerides present at a concentration ranging from 7% w/w to 13% w/w;
(b3) polysorbate 80 present at a concentration from 7% w/w to 13% w/w;
(c) dl-alpha-tocopherol present at a concentration ranging from 0.5% w/w to 1% w/w; and
(d) glyceryl monooleate.

### Claim 33 (depends on 32)

The method of claim 32, wherein the Compound A is administered as a soft gelatin capsule being prepared by a method comprising adding Compound A to a mixture comprising 33% w/w to 43% w/w glyceryl monooleate, glycerol monocaprylocaprate, caprylocaproyl polyoxyl-8 glycerides, polysorbate 80, or dl-alpha-tocopherol.

### Claim 34 (depends on 1)

The method of claim 1, wherein the Compound A is administered as a soft gelatin capsule comprising:
a) Compound A present at a concentration ranging from 5% w/w to 10% w/w;
(b1) glycerol monocaprylocaprate present at a concentration ranging from 20% w/w to 65% w/w;
(b2) caprylocaproyl polyoxyl-8 glycerides present at a concentration ranging from 7% w/w to 13% w/w;
(b3) polysorbate 80 present at a concentration from 7% w/w to 13% w/w;
(c) dl-alpha-tocopherol present at a concentration ranging from 0.5% w/w to 1% w/w; and
(d) glyceryl monooleate present at a concentration ranging from 33% w/w to 43% w/w.
